News
NWBO
0.670
-1.47%
-0.010
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr...
PR Newswire · 06/06 01:23
Northwest Bio plunges after late-stage data for lead candidate in brain cancer
The shares of Northwest Biotherapeutics (OTCQB:NWBO) reached a 52-week low on Tuesday after the clinical-stage immunotherapy company announced a presentation with Phase 3 data for its lead asset DCVax-L in
Seekingalpha · 05/10 16:52
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic C...
PR Newswire · 05/10 14:19
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Gliobl...
PR Newswire · 05/04 15:35
If You Invested $1000 In Northwest Biotherapeutics 5 Years Ago, Here's How Much You Would Have Today
Northwest Biotherapeutics (OTC:NWBO) has outperformed the market over the past 5 years by 42.99% on an annualized basis producing an average annual return of 54.57%. Currently, Northwest Biotherapeutics has a market capitalization of $1.42 billion.
Benzinga · 05/03 15:03
Northwest stock rises 9% as company begins cancer vaccine production at UK facility
Northwest Biotherapeutics (OTCQB:NWBO +7.6%) began production of its first dendritic cell cancer vaccine for a compassionate use patient at its production facility in Sawston, U.K. The company said the milestone follows
Seekingalpha · 02/17 14:49
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate u...
PR Newswire · 02/17 14:20
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Ag...
PR Newswire · 12/21/2021 14:24
Northwest Biotherapeutics secures $15M financing on stock purchase rights
Northwest Biotherapeutics (OTCQB:NWBO +12.3%) has closed on $15M financing, which brings the company's cash reserves above $20M. The financing is in the form of a 22-month loan which requires no
Seekingalpha · 11/29/2021 16:11
Northwest Bio gaining attention as investors await phase 3 GBM data
Interest in Northwest Bio (NWBO) has increased in recent days as some investors feel that the company is poised to release strong phase 3 data on its brain cancer treatment
Seekingalpha · 05/24/2021 15:16
Traders Have Rotated Into Big Multinational Companies On OTC Markets
One of the ways we gauge market sentiment is by looking at rotation—which areas of the market, traders and investors are most bullish or bearish on, and watching how those trends change over time.  We can track this by looking at price (the upward or downward pressure on an asset) as well as by volume (where the most attention is being paid). 
Benzinga · 10/27/2020 12:04
Northwest Bio, Wow!
With Data Lock just announced, Top Line Date is imminent.Numerous statistical and mathematical markers from available data shine a positive light on potential trial results.The company may have a lucrative option even if median Overall Survival does not meet the secondary endpoints.
Seekingalpha · 10/09/2020 20:12
Northwest Biotherapeutics locks Phase III trial data
Northwest Biotherapeutics ([[NWBO]] +2.6%) announced that the database for the Phase III trial of DCVax-L for Gliobastoma has been locked.Pipeline:Independent service firms managing the clinical trial will now arrange for the
Seekingalpha · 10/05/2020 13:52
Northwest Biotherapeutics locks Phase 3 data from brain tumor study
Northwest Biotherapeutics ([[NWBO]] +2.6%) announced that the database for the Phase 3 trial of DCVax-L for Gliobastoma has been locked, which means that only the firms managing the trial will have
Seekingalpha · 10/05/2020 13:52
Northwest Biotherapeutics high on Flaskworks acquisition
Executed and closed on August 28, 2020, Northwest Biotherapeutics ([[NWBO]] +5.4%) acquired Flaskworks, a developer of breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax,
Seekingalpha · 09/01/2020 15:18
Northwest Biotherapeutics secures loan financing of $5M
Northwest Biotherapeutics ([[NWBO]] +2.0%) has completed a non-dilutive debt financing for net proceeds of additional $5M, via a 21-month note for $5.5M at an 8% annualized interest rate, with no payments due
Seekingalpha · 08/21/2020 15:35
Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company's Phase 3 trial o
PR Newswire · 07/24/2020 13:31
Denovo Biopharma's enzastaurin Fast Track'd for brain tumor
The FDA designates privately held Denovo Biopharma's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblas
seekingalpha · 07/17/2020 17:18
NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.
PR Newswire · 06/02/2020 13:35
NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
PR Newswire · 04/18/2020 17:05
More
Webull provides a variety of real-time NWBO stock news. You can receive the latest news about Northwest Bio through multiple platforms. This information may help you make smarter investment decisions.
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.